The FDA announced that the heartburn drug, Reglan, and all other drugs containing metoclopramide will carry the administration’s strongest “black box” warning. The change was made to alert consumers, and health care professionals of an increased risk of developing tardive dyskinesia.
Tardive Dyskinesia is a repetitive involuntary movement disorder.